PCSK9 inhibitor safety screen: two signals, both likely bias

Design

Sequence symmetry analysis in French national data with ezetimibe comparator, plus WHO database disproportionality analysis

Population

36,163 PCSK9 inhibitor initiators and 34,269 ezetimibe initiators, 2018 to 2023

Primary outcome

Potential safety signals across about 700 outcomes

Effect

Two signals: inhaled glucocorticoids (adjusted SR 1.19, 95% CI 1.06 to 1.35) and colony-stimulating factors (adjusted SR 2.25, 95% CI 1.37 to 4.17); none confirmed in the WHO database

French investigators looked for unexpected safety signals for PCSK9 inhibitors using a sequence symmetry analysis in the national health database. Initiators from 2018 to 2023 were matched to ezetimibe initiators to control for temporal trends and indication. The analysis covered 36,163 PCSK9 inhibitor and 34,269 ezetimibe initiators across about 700 outcomes, with a signal defined as both crude and ezetimibe-adjusted sequence ratios having a lower confidence limit above 1. Designated medical events were also checked in the WHO database.

Two signals emerged: later initiation of inhaled glucocorticoids (crude 1.25, adjusted 1.19, 95% CI 1.06 to 1.35) and of colony-stimulating factors (crude 4.22, adjusted 2.25, 95% CI 1.37 to 4.17). No related signal was found in the WHO database. The authors judge both likely to reflect residual indication bias or confounding.

Sequence symmetry analysis detects patterns of new prescriptions, not diagnoses, and it is a screening tool that generates hypotheses. The absence of other signals is reassuring but does not exclude rare events. For an Indian clinic, PCSK9 inhibitors are used rarely and cost limits access.

• Continue to use PCSK9 inhibitors where indicated; this screen found no new safety concern.
• Report unexpected adverse events to your pharmacovigilance programme.
• Do not treat the two signals as proven effects; the authors attribute them to bias.
• Review lipid targets and statin use before escalating to a PCSK9 inhibitor.

Why it matters

It is a systematic check for the unexpected, and it came back largely clean.

Don't overread it

A negative screening result does not exclude rare events, and the two signals are hypotheses, not findings.

The statistics, in plain English

A sequence ratio above 1 means a drug class was started more often after the PCSK9 inhibitor than before it. When screening about 700 outcomes, a few will pass any threshold by chance or through confounding, which is why signals are confirmed in a second dataset.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.